{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:04:06Z","timestamp":1792843446840,"version":"4.5.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>Neuroprotective strategies aimed at preventing secondary neurologic injury following acute spinal cord injury remain an important area of clinical, translational, and basic science research. Despite recent advancement in the understanding of basic mechanisms of primary and secondary neurologic injury, few pharmacologic agents have shown consistent promise in improving neurologic outcomes following SCI in large randomized clinical trials. The authors review the existing literature and clinical guidelines for pharmacologic therapy investigated for managing acute SCI, including corticosteroids, GM-1 ganglioside (Sygen), Riluzole, opioid antagonists, Cethrin, minocycline, and vasopressors for mean arterial pressure augmentation. Therapies for managing secondary effects of SCI, such as bradycardia, are discussed. Current clinical trials for pharmacotherapy and cellular transplantation following acute SCI are also reviewed. Despite the paucity of current evidence for clinically beneficial post-SCI pharmacotherapy, future research efforts will hopefully elucidate promising therapeutic agents to improve neurologic function.<\/jats:p>","DOI":"10.1097\/bsd.0000000000001695","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T16:14:36Z","timestamp":1726157676000},"page":"433-439","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacologic Therapy for Spinal Cord Injury"],"prefix":"10.1097","volume":"37","author":[{"given":"Brandon A.","family":"Sherrod","sequence":"first","affiliation":[{"name":"Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Porche","sequence":"additional","affiliation":[{"name":"Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad K.","family":"Condie","sequence":"additional","affiliation":[{"name":"Pharmacy, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Dailey","sequence":"additional","affiliation":[{"name":"Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"R1-20250621","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sc.2012.158","article-title":"The global map for traumatic spinal cord injury epidemiology: update 2011, global incidence rate","volume":"52","author":"Lee","year":"2014","journal-title":"Spinal Cord"},{"key":"R3-20250621","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/BRS.0000000000004417","article-title":"Spinal cord injury: the global incidence, prevalence, and disability from the Global Burden of Disease Study 2019","volume":"47","author":"Ding","year":"2022","journal-title":"Spine (Phila Pa 1976)"},{"key":"R4-20250621","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nec.2016.07.002","article-title":"Pharmacologic management of acute spinal cord injury","volume":"28","author":"Karsy","year":"2017","journal-title":"Neurosurg Clin N Am"},{"key":"R5-20250621","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.spinee.2003.07.007","article-title":"Pathophysiology and pharmacologic treatment of acute spinal cord injury","volume":"4","author":"Kwon","year":"2004","journal-title":"Spine J"},{"key":"R6-20250621","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14728222.2019.1661381","article-title":"Emerging molecular therapeutic targets for spinal cord injury","volume":"23","author":"Wang","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"R7-20250621","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.1984.03340250025015","article-title":"Efficacy of methylprednisolone in acute spinal cord injury","volume":"251","author":"Bracken","year":"1984","journal-title":"JAMA"},{"key":"R8-20250621","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199005173222001","article-title":"A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second National Acute Spinal Cord Injury Study","volume":"322","author":"Bracken","year":"1990","journal-title":"N Engl J Med"},{"key":"R9-20250621","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jama.1997.03540440031029","article-title":"Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study","volume":"277","author":"Bracken","year":"1997","journal-title":"JAMA"},{"key":"R10-20250621","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1056\/NEJM199106273242601","article-title":"Recovery of motor function after spinal-cord injury\u2014a randomized, placebo-controlled trial with GM-1 ganglioside","volume":"324","author":"Geisler","year":"1991","journal-title":"N Engl J Med"},{"key":"R11-20250621","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/aws072","article-title":"Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury","volume":"135","author":"Casha","year":"2012","journal-title":"Brain"},{"key":"R12-20250621","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1089\/neu.2023.0163","article-title":"Safety and efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): a multi-center, randomized, placebo-controlled, double-blinded trial","volume":"40","author":"Fehlings","year":"2023","journal-title":"J Neurotrauma"},{"key":"R13-20250621","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1089\/neu.2020.7096","article-title":"A randomized controlled trial of local delivery of a rho inhibitor (VX-210) in patients with acute traumatic cervical spinal cord injury","volume":"38","author":"Fehlings","year":"2021","journal-title":"J Neurotrauma"},{"issue":"Suppl 1","key":"R14-20250621","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1227\/01.neu.0000462080.04196.f7","article-title":"Pharmacological therapy for acute spinal cord injury","volume":"76","author":"Hurlbert","year":"2015","journal-title":"Neurosurgery"},{"key":"R15-20250621","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1093\/neuros\/nyy371","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines on the evaluation and treatment of patients with thoracolumbar spine trauma: pharmacological treatment","volume":"84","author":"Arnold","year":"2019","journal-title":"Neurosurgery"},{"issue":"Suppl 2","key":"R16-20250621","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1227\/NEU.0b013e31827765c6","article-title":"Pharmacological therapy for acute spinal cord injury","volume":"72","author":"Hurlbert","year":"2013","journal-title":"Neurosurgery"},{"key":"R17-20250621","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/00006123-200203001-00013","article-title":"Pharmacological therapy after acute cervical spinal cord injury","volume":"50","author":"Hadley","year":"2002","journal-title":"Neurosurgery"},{"key":"R18-20250621","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1227\/01.neu.0000430319.32247.7f","article-title":"Guidelines for the management of acute cervical spine and spinal cord injuries: 2013 update","volume":"60","author":"Walters","year":"2013","journal-title":"Neurosurgery"},{"key":"R19-20250621","doi-asserted-by":"crossref","first-page":"116S","DOI":"10.1177\/2192568217706366","article-title":"Efficacy and safety of methylprednisolone sodium succinate in acute spinal cord injury: a systematic review","volume":"7","author":"Fehlings","year":"2017","journal-title":"Global Spine J"},{"key":"R20-20250621","doi-asserted-by":"crossref","first-page":"203S","DOI":"10.1177\/2192568217703085","article-title":"A clinical practice guideline for the management of patients with acute spinal cord injury: recommendations on the use of methylprednisolone sodium succinate","volume":"7","author":"Fehlings","year":"2017","journal-title":"Global Spine J"},{"key":"R22-20250621","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.3171\/2017.8.FOCUS17428","article-title":"The impact of blood pressure management after spinal cord injury: a systematic review of the literature","volume":"43","author":"Saadeh","year":"2017","journal-title":"Neurosurg Focus"},{"key":"R23-20250621","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3171\/jns.1997.87.2.0239","article-title":"Combined medical and surgical treatment after acute spinal cord injury: results of a prospective pilot study to assess the merits of aggressive medical resuscitation and blood pressure management","volume":"87","author":"Vale","year":"1997","journal-title":"J Neurosurg"},{"key":"R24-20250621","first-page":"1007","article-title":"Hemodynamic parameters in patients with acute cervical cord trauma: description, intervention, and prediction of outcome","volume":"33","author":"Levi","year":"1993","journal-title":"Neurosurgery"},{"key":"R25-20250621","first-page":"1","article-title":"Mean arterial pressure (MAP) augmentation in traumatic spinal cord injuries: early hyperperfusion treatment influences neurologic outcomes","author":"LaRiccia","year":"2023","journal-title":"J Spinal Cord Med"},{"key":"R26-20250621","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3171\/2015.2.SPINE14746","article-title":"Complications and outcomes of vasopressor usage in acute traumatic central cord syndrome","volume":"23","author":"Readdy","year":"2015","journal-title":"J Neurosurg Spine"},{"key":"R27-20250621","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/TA.0000000000002953","article-title":"Mean arterial pressure maintenance following spinal cord injury: does meeting the target matter?","volume":"90","author":"Weinberg","year":"2021","journal-title":"J Trauma Acute Care Surg"},{"key":"R28-20250621","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.1093\/neuros\/nyy368","article-title":"Congress of neurological surgeons systematic review and evidence-based guidelines on the evaluation and treatment of patients with thoracolumbar spine trauma: hemodynamic management","volume":"84","author":"Dhall","year":"2019","journal-title":"Neurosurgery"},{"key":"R29-20250621","doi-asserted-by":"crossref","first-page":"187S","DOI":"10.1177\/21925682231202348","article-title":"A clinical practice guideline for the management of patients with acute spinal cord injury: recommendations on hemodynamic management","volume":"14","author":"Kwon","year":"2024","journal-title":"Global Spine J"},{"key":"R30-20250621","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/21925682221116888","article-title":"Current practice of acute spinal cord injury management: a global survey of members from the AO spine","volume":"14","author":"Hejrati","year":"2024","journal-title":"Global Spine J"},{"key":"R31-20250621","doi-asserted-by":"crossref","DOI":"10.1227\/neu.0000000000002375_103","article-title":"Cerebrospinal fluid drainage in patients with acute spinal cord injury: a multi-center randomized controlled trial","author":"Theodore","year":"2023","journal-title":"World Neurosurg"},{"key":"R32-20250621","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.wneu.2019.09.044","article-title":"Clinical implementation of novel spinal cord perfusion pressure protocol in acute traumatic spinal cord injury at U.S. level I trauma center: TRACK-SCI Study","volume":"133","author":"Yue","year":"2020","journal-title":"World Neurosurg"},{"key":"R33-20250621","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3171\/2008.10.SPINE08217","article-title":"Intrathecal pressure monitoring and cerebrospinal fluid drainage in acute spinal cord injury: a prospective randomized trial","volume":"10","author":"Kwon","year":"2009","journal-title":"J Neurosurg Spine"},{"key":"R34-20250621","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1212\/WNL.0000000000008125","article-title":"Empirical targets for acute hemodynamic management of individuals with spinal cord injury","volume":"93","author":"Squair","year":"2019","journal-title":"Neurology"},{"key":"R35-20250621","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.0000000000004519","article-title":"Spinal cord perfusion pressure predicts neurologic recovery in acute spinal cord injury","volume":"89","author":"Squair","year":"2017","journal-title":"Neurology"},{"key":"R36-20250621","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sc.2016.79","article-title":"The differential effects of norepinephrine and dopamine on cerebrospinal fluid pressure and spinal cord perfusion pressure after acute human spinal cord injury","volume":"55","author":"Altaf","year":"2017","journal-title":"Spinal Cord"},{"key":"R37-20250621","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jcp.47.4.300","article-title":"IgM ganglioside GM1 antibodies in patients with autoimmune disease or neuropathy, and controls","volume":"47","author":"Bansal","year":"1994","journal-title":"J Clin Pathol"},{"key":"R38-20250621","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1097\/00007632-200112151-00015","article-title":"The Sygen multicenter acute spinal cord injury study","volume":"26","author":"Geisler","year":"2001","journal-title":"Spine (Phila Pa 1976)"},{"key":"R39-20250621","doi-asserted-by":"crossref","first-page":"E383","DOI":"10.1227\/01.neu.0000430301.48455.4b","article-title":"Guidelines for GM-1 in acute spinal cord injury","volume":"73","author":"Geisler","year":"2013","journal-title":"Neurosurgery"},{"key":"R40-20250621","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.3390\/molecules20057775","article-title":"Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside","volume":"20","author":"Nagoshi","year":"2015","journal-title":"Molecules"},{"key":"R41-20250621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2018.9.SPINE18682","article-title":"Time is spine: a review of translational advances in spinal cord injury","volume":"30","author":"Badhiwala","year":"2018","journal-title":"J Neurosurg Spine"},{"key":"R42-20250621","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1089\/neu.2022.0499","article-title":"Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) sub-study: an analysis of pharmacokinetics, pharmacodynamics, and impact on xonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial","volume":"40","author":"Chow","year":"2023","journal-title":"J Neurotrauma"},{"key":"R43-20250621","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1007\/s43465-022-00758-6","article-title":"The role of riluzole in acute traumatic cervical spinal cord injury with incomplete neurological deficit: a prospective, randomised controlled study","volume":"56","author":"Kumarasamy","year":"2022","journal-title":"Indian J Orthop"},{"key":"R44-20250621","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1474-4422(20)30407-5","article-title":"Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Fehlings","year":"2021","journal-title":"Lancet Neurol"},{"key":"R45-20250621","doi-asserted-by":"crossref","first-page":"e2415643","DOI":"10.1001\/jamanetworkopen.2024.15643","article-title":"Riluzole for degenerative cervical myelopathy: a secondary analysis of the CSM-PROTECT Trial","volume":"7","author":"Fehlings","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R46-20250621","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.spinee.2022.09.009","article-title":"A critical appraisal of clinical practice guidelines on pharmacological treatments for spinal cord injury","volume":"23","author":"Guan","year":"2023","journal-title":"Spine J"},{"key":"R47-20250621","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.injury.2015.05.018","article-title":"Protective effects of minocycline on experimental spinal cord injury in rats","volume":"46","author":"Aras","year":"2015","journal-title":"Injury"},{"key":"R48-20250621","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.2174\/1381612811319240007","article-title":"Rho as a target to promote repair: translation to clinical studies with cethrin","volume":"19","author":"McKerracher","year":"2013","journal-title":"Curr Pharm Des"},{"key":"R49-20250621","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.201302-0388PP","article-title":"Theophylline","volume":"188","author":"Barnes","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R50-20250621","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/08971900211064701","article-title":"Theophylline for spinal cord injury associated bradycardia","volume":"36","author":"Perrine","year":"2023","journal-title":"J Pharm Pract"},{"key":"R51-20250621","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s12028-021-01384-0","article-title":"Impact of enteral albuterol on bradycardic events after acute cervical spinal cord injury","volume":"36","author":"Lim-Hing","year":"2022","journal-title":"Neurocrit Care"},{"key":"R52-20250621","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1474-4422(23)00215-6","article-title":"Soluble Nogo-receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial","volume":"22","author":"Maynard","year":"2023","journal-title":"Lancet Neurol"},{"key":"R53-20250621","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3171\/2022.5.SPINE22167","article-title":"A phase 1\/2a dose-escalation study of oligodendrocyte progenitor cells in individuals with subacute cervical spinal cord injury","volume":"37","author":"Fessler","year":"2022","journal-title":"J Neurosurg Spine"},{"key":"R54-20250621","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1111\/bcp.15854","article-title":"Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-beta agonist for treatment of spinal cord injury, in male healthy participants","volume":"89","author":"Goncalves","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R55-20250621","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s40265-023-01922-4","article-title":"Sovateltide: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"R56-20250621","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1089\/neu.2019.6854","article-title":"Phase I\/II study of intrathecal administration of recombinant human hepatocyte growth factor in patients with acute spinal cord injury: a double-blind, randomized clinical trial of safety and efficacy","volume":"37","author":"Nagoshi","year":"2020","journal-title":"J Neurotrauma"},{"key":"R57-20250621","doi-asserted-by":"crossref","first-page":"e031329","DOI":"10.1136\/bmjopen-2019-031329","article-title":"SCING-spinal cord injury neuroprotection with glyburide: a pilot, open-label, multicentre, prospective evaluation of oral glyburide in patients with acute traumatic spinal cord injury in the USA","volume":"9","author":"Minnema","year":"2019","journal-title":"BMJ Open"},{"key":"R58-20250621","doi-asserted-by":"crossref","first-page":"105812","DOI":"10.1016\/j.nbd.2022.105812","article-title":"Delayed administration of elezanumab, a human anti-RGMa neutralizing monoclonal antibody, promotes recovery following cervical spinal cord injury","volume":"172","author":"Mothe","year":"2022","journal-title":"Neurobiol Dis"},{"key":"R59-20250621","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1545968318776371","article-title":"First-in-man intrathecal application of neurite growth-promoting anti-nogo-A antibodies in acute spinal cord injury","volume":"32","author":"Kucher","year":"2018","journal-title":"Neurorehabil Neural Repair"},{"key":"R60-20250621","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/glia.20934","article-title":"Corticospinal tract regeneration after spinal cord injury in receptor protein tyrosine phosphatase sigma deficient mice","volume":"58","author":"Fry","year":"2010","journal-title":"Glia"}],"container-title":["Clinical Spine Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BSD.0000000000001695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:01:12Z","timestamp":1750539672000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BSD.0000000000001695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bsd.0000000000001695","relation":{},"ISSN":["2380-0186"],"issn-type":[{"value":"2380-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"2024-07-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}